Top Analyst Upgrades and Downgrades: Bluebird Bio, Boston Beer, Etsy, Gilead, Pfizer, PMC-Sierra, Valeant and More
Stocks were down marginally on Tuesday morning, and indicated much better than the early-bird lows. Investors keep indicating that they will buy their favorite stocks and other value stocks or opportunities when the opportunity is there.
24/7 Wall St. reviews dozens of analyst research reports each day to find new investing and trading ideas for our readers. Some analyst research reports cover stocks to buy and others cover stocks to sell or avoid. These are this Tuesday’s top analyst upgrades, downgrades and initiations.
Bluebird Bio Inc. (NASDAQ: BLUE) was started as Outperform with a $162.00 price target (versus an $81.83 prior close) at Oppenheimer. Bluebird dropped over 4% to $81.83 on Monday and was indicated lower on Tuesday on the heels of a presentation at an anemia symposium on Monday. Bluebird shares have a 52-week trading range of $35.00 to $197.35.
Boston Beer Co. (NYSE: SAM) was raised to Neutral from Sell and the price target was raised to $244.00 from $208.00 (versus a $241.34 close) at Goldman Sachs.
Etsy Inc. (NASDAQ: ETSY) was raised to Neutral from Underperform at Wedbush Securities, but the $9.00 price target is under the $10.94 prior close. Etsy has a consensus target above $14.00 and a post-IPO range of $10.29 to $35.74.
Gilead Sciences Inc. (NASDAQ: GILD) was reiterated as Outperform at Oppenheimer, and the firm raised its price target up to $124.00 from $120.00 (versus a $103.61 close). The consensus analyst price target is $124.25, and the 52-week range is $85.95 to $123.37.
Pfizer Inc. (NYSE: PFE) was raised to Outperform from Market Perform and the $35.00 prior price target was raised to $43.00 (versus a $34.50 close) at Cowen. The consensus price target is $39.33. The 52-week range is $28.00 to $36.46.
PMC-Sierra Inc. (NASDAQ: PMCS) has now received a higher bid of $11.35 and it closed at $11.75 on Monday. The chipmaker was downgraded to Market Perform from Outperform with an $11.00 price target at Northland Securities.
Valeant Pharmaceuticals International Inc. (NYSE: VRX) was downgraded to Sector Perform from Sector Outperform at CIBC. Valeant closed down 7.7% at $163.83 on Monday, against a 52-week range of $123.96 to $263.81.
Other key analyst upgrades, downgrades and initiations seen on Tuesday were in the following: